Back to Newsroom

Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting

LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients with advanced solid tumors or lymphomas at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from June 2-6 in Chicago.